iShares Core S&P Small-Cap
Latest iShares Core S&P Small-Cap News and Updates
Wall Street’s Forecast for Flotek Industries before Its 3Q17 Earnings
On October 16, 2017, all analysts tracking Flotek Industries rated it as a “buy” or some equivalent.Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta
Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?
Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.
